{"nct_id":"NCT02041533","title":"An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)","status":"COMPLETED","status_verified_date":"2023-02","start_date":"2014-03-27","start_date_type":"ACTUAL","primary_completion_date":"2016-07-01","primary_completion_date_type":"ACTUAL","completion_date":"2022-05-27","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["BMY"]}